KRAS and colorectal carcinoma: In 68 patients with colorectal carcinoma (CRC), key driver mutations were detected as follows: KRAS, 40 (59%); NRAS, 1 (1%); BRAF, 4 (6%); ERBB2, 2 (3%); and ERBB3, 1 (1%).